ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)

被引：0

作者：

Smith, M. R. ^{[1
]}

Parker, C. C. ^{[2
]}

Saad, F. ^{[3
]}

Miller, K. ^{[4
]}

Tombal, B. ^{[5
]}

Ng, Q. S. ^{[6
]}

Boegemann, M. ^{[7
]}

Matveev, V. ^{[8
]}

Piulats, J. M. ^{[9
]}

Zucca, L. E. ^{[10
]}

Heidenreich, A. ^{[11
]}

Kakehi, Y. ^{[12
]}

Zhang, A. ^{[13
]}

Krissel, H. ^{[14
]}

Shen, J. ^{[15
]}

Wagner, V. ^{[16
]}

Higano, C. ^{[17
,18
]}

机构：

[1] Massachusetts Gen Hosp, Dept Oncol, Boston, MA 02114 USA

[2] Royal Marsden NHS Fdn Trust, Dept Urol, Inst Canc Res, Sutton, Surrey, England

[3] Univ Montreal Hosp Ctr, Dept Urol, Montreal, PQ, Canada

[4] Charite, Dept Med Oncol, Berlin, Germany

[5] Clin Univ St Luc, Dept Urol, Brussels, Belgium

[6] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[7] Univ Munster, Med Ctr, Dept Clin Oncol Urol, Munster, Germany

[8] NN Blokhin Canc Res Ctr, Dept Urol, Moscow, Russia

[9] Catalan Canc Inst, Dept Med Oncol, Barcelona, Spain

[10] Barretos Canc Hosp, Dept Med Oncol, Barretos, Brazil

[11] Univ Hosp Cologne, Dept Urol, Cologne, Germany

[12] Kagawa Univ, Dept Urol, Takamatsu, Kagawa, Japan

[13] Bayer HealthCare Pharmaceut, Oncol, Whippany, NJ USA

[14] Bayer AG, Oncol, Berlin, Germany

[15] Bayer HealthCare Pharmaceut, Clin Stat, Whippany, NJ USA

[16] Bayer Consumer Care AG, Oncol, Basel, Switzerland

[17] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA

[18] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA30

引用

页数：1

共 50 条

[31] Clinical outcomes of a Dutch prospective observational registry of metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223 (Ra-223).
Louhanepessy, Rebecca
Badrising, Sushil
van der Noort, Vincent
Coenen, Jules L. L. M.
Hamberg, Paul
Beeker, Aart
Wagenaar, Nils
Lam, Marnix G. E. H.
Celik, Filiz
Loosveld, Olaf
Oostdijk, Ad
Zuetenhorst, Johanna Maria
Vegt, Erik
Zwart, Wilbert
Bergman, Andre M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[32] Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra-223) (BIO-Ra-223 study).
Rebuzzi, Sara Elena
Bauckneht, Matteo
Signori, Alessio
Frantellizzi, Viviana
Rizzini, Elisa Lodi
Mascia, Manlio
Lavelli, Valentina
Stazza, Maria Lina
Licari, Maria
Donegani, Maria Isabella
Ponzano, Marta
Cavallini, Letizia
Laghi, Viola
Cindolo, Luca
Costa, Renato Patrizio
Spanu, Angela
Rubini, Giuseppe
Monari, Fabio
De Vincentis, Giuseppe
Fornarini, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[33] Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A US tertiary oncology center analysis
McKay, Rana R.
Silver, Rebecca
Bhak, Rachel
Korves, Caroline
Cheng, Mu
Appukkuttan, Sreevalsa
Simmons, Stacey J.
Duh, Mei Sheng
Taplin, Mary-Ellen
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[34] A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study
Nobuaki Matsubara
Go Kimura
Hiroji Uemura
Hirotsugu Uemura
Motonobu Nakamura
Satoshi Nagamori
Atsushi Mizokami
Hiroaki Kikukawa
Makoto Hosono
Seigo Kinuya
Heiko Krissel
Jonathan Siegel
Yoshiyuki Kakehi
International Journal of Clinical Oncology, 2020, 25 : 720 - 731
[35] A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study
Matsubara, Nobuaki
Kimura, Go
Uemura, Hiroji
Uemura, Hirotsugu
Nakamura, Motonobu
Nagamori, Satoshi
Mizokami, Atsushi
Kikukawa, Hiroaki
Hosono, Makoto
Kinuya, Seigo
Krissel, Heiko
Siegel, Jonathan
Kakehi, Yoshiyuki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (04) : 720 - 731
[36] Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.
James, Nicholas D.
Heinrich, Daniel
Castro, Elena
George, Saby
Song, Daniel Y.
Dizdarevic, Sabina
Baldari, Sergio
Essler, Markus
De Jong, Igle Jan
Lastoria, Secondo
Hammerer, Peter G.
Meltzer, Jeffrey
Sandstrom, Per
Verholen, Frank
Tombal, Bertrand F.
O'Sullivan, Joe M.
Sartor, A. Oliver
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[37] Fractionated docetaxel and radium-223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A phase I trial.
Connell, Brendan James
Folefac, Edmund
Hwang, Clara
Lawlor, Christian
Mathew, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[38] UTILIZATION OF RADIUM-223 DICHLORIDE (RA-223) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA: A REAL-WORLD RETROSPECTIVE STUDY
Lapierre, M.
Fraelic, A.
VALUE IN HEALTH, 2016, 19 (03) : A162 - A162
[39] Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
Nilsson, Sten
Sartor, A. Oliver
Bruland, Oyvind S.
Fang, Fang
Aksnes, Anne-Kirsti
Parker, Chris
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
[40] Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases
Widmark, A.
Helle, S. I.
James, N.
Larsson, A.
Staudacher, K.
Haugen, I.
Garcia-Vargas, J.
Nilsson, S.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S189 - S190

← 1 2 3 4 5 →